2026-04-29T17:03:11Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/187192024-02-27T15:10:02Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Moya-García, Aurelio A
author
González-Jiménez, Andrés
author
Moreno, Fernando
author
Stephens, Camilla
author
Lucena, María Isabel
author
Ranea, Juan A G
2024-02-27T15:10:02Z
2024-02-27T15:10:02Z
2022-07-21
10.3390/genes13071292
2073-4425
Genes
http://hdl.handle.net/10668/20981
35886075
http://hdl.handle.net/20.500.12105/18719
Among adverse drug reactions, drug-induced liver injury presents particular challenges because of its complexity, and the underlying mechanisms are still not completely characterized. Our knowledge of the topic is limited and based on the assumption that a drug acts on one molecular target. We have leveraged drug polypharmacology, i.e., the ability of a drug to bind multiple targets and thus perturb several biological processes, to develop a systems pharmacology platform that integrates all drug-target interactions. Our analysis sheds light on the molecular mechanisms of drugs involved in drug-induced liver injury and provides new hypotheses to study this phenomenon.
eng
drug-induced liver injury
polypharmacology
systems pharmacology
toxicology
Identification of New Toxicity Mechanisms in Drug-Induced Liver Injury through Systems Pharmacology.
research article